Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenqi Yishen Granules in IgA Nephropathy
NCT07360002Not yet recruiting
- Sponsor
- Keda Luye
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of Shenqi Yishen Granules in IgA nephropathy (IgAN) (2 arms), sponsored by Keda Luye. Primary endpoints: 24-hour urinary protein quantification at 12 weeks and Protein-to-creatinine ratio at 12 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
Shenqi Yishen Granules
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07360002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07360002.